Clinical trials
Other Solid Tumors clinical trials
Below are recruiting other solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,667 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT07378436RecruitingEarly Phase 1
Testing a new drug for cancer-related belly fluid
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
BeijingAges 18–75 - NCT05098847RecruitingPhase 2
Freezing liver tumors plus anti-cancer drugs for spread cancer
This trial tests whether freezing (cryoablation) liver metastases works better when combined with immunotherapy (sintilimab) and a targeted pill (lenvatinib). It’s for people whose cancer has spread to the liver and has not responded to earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07354711RecruitingPhase 1/Phase 2
Study of 3H-10000 for advanced solid tumors
This trial tests a new drug called 3H-10000 for people with solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06350539Recruiting
Personalized Cancer Models Research Study
This study aims to create personalized models (like miniature tumors in a dish) from your cells to better understand your cancer and find new ways to treat it. Both people with solid tumors and healthy volunteers are welcome to participate.
New York, New YorkAges 18 years+ - NCT07318805RecruitingPhase 1
A study of PF-08032562 for advanced solid tumors
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07302347RecruitingPhase 1/Phase 2
Study of pembrolizumab for different cancers in Japan
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Nagoya, Aichi-kenAges 6 months+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT07292038RecruitingPhase 1
Testing NM6603 in advanced solid tumors
This study tests an experimental oral drug called NM6603 in people with advanced solid tumors, especially colorectal cancer or triple-negative breast cancer. It aims to find a safe dose and see how the drug works in the body.
Xiamen, FujianAges 18–75 - NCT07296341RecruitingPhase 1/Phase 2
HRS-4642 plus other therapies for pancreatic cancer
This study tests an experimental drug (HRS-4642) combined with other cancer treatments for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07281326RecruitingPhase 1
A study of AK138D1 for advanced solid tumors
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
Harbin, HeilongjiangAges 18–75 - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Tampa, FloridaAges 18 years+ - NCT07277270RecruitingPhase 1
Study of a new drug with standard treatments for advanced solid tumors
This trial tests a new investigational drug called GSK5764227 when given along with standard cancer treatments or other drugs for people with advanced colorectal or prostate cancer that has spread and cannot be removed by surgery.
Reunion, FloridaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Princeton, New JerseyAges 18 years+ - NCT07269080RecruitingPhase 1
Radiation plus immunotherapy for advanced solid tumors
This trial tests whether adding targeted radiation to your metastatic tumors can help your immunotherapy work better. It is for people with advanced solid tumors that have spread to 3-10 spots and who have been on immunotherapy for at least 3 months.
Chicago, IllinoisAges 18 years+ - NCT05483400RecruitingPhase 2
Atezolizumab and tiragolumab study for several solid tumors
This Phase 2 trial tests the cancer medicines atezolizumab and tiragolumab in people with different solid tumors. It aims to see how well these drugs work and what side effects they cause in specific patient groups.
GroningenAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07249775Recruiting
Study of new drug FID-022 for pancreatic cancer
This trial tests a new study drug called FID-022 for people with pancreatic cancer. It is a first-in-human study, meaning it is the first time this drug is being tested in people, and researchers want to see if it is safe and how it works.
Tampa, FloridaAges 18 years+ - NCT07259226RecruitingPhase 2
Studying resistance to antibody-drug conjugates in advanced cancer
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
VillejuifAges 18 years+ - NCT07246863RecruitingPhase 2
Testing visugromab and nivolumab with or without docetaxel for advanced lung cancer
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
Birmingham, AlabamaAges 18 years+ - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
New Brunswick, New JerseyAges 18 years+ - NCT07244835RecruitingPhase 1
A study of DEG6498 for advanced solid tumors
This trial tests a new drug, DEG6498, for people with advanced solid tumors that have not responded to other treatments. It may be an option if your cancer has a BRAF mutation or is a type of liver cancer called HCC.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other solid tumors?
- Yes. Clin2 currently lists 1,667 recruiting other solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.